AngioDynamics
AngioDynamics is a medical technology company focused on vascular and oncology devices and minimally invasive solutions.
Last updated September 25, 2026
AI crawler reads
2requests
1companies- Anthropic2
- Profile
- 2
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
AngioDynamics is a medical technology company whose portfolio serves cardiovascular and oncologic care. The company describes its work as focused on restoring healthy blood flow in the vascular system, expanding cancer treatment options, and improving quality of life for patients. Its products are intended to give physicians tools for diagnosing and treating cardiovascular and oncologic diseases. The company presents its technologies as minimally invasive medical solutions and says its devices support healthcare professionals around the world in delivering patient care. Its stated focus is on high-quality treatment and improved patient outcomes for people facing challenging diseases. The supplied company materials describe the relevant fields and purpose of its portfolio, but do not identify particular products, founding details, ownership, headquarters, or commercial listing information. AngioDynamics’ leadership page identifies Jim Clemmer as President, Chief Executive Officer, and Director. Its listed leadership team also includes executives responsible for finance, information technology, communications, corporate development and strategy, scientific and clinical affairs, legal affairs, cardiovascular and international operations, supply chain and regulatory affairs, human resources, and oncology and interventional devices.
History
The supplied evidence establishes AngioDynamics as a company operating in medical technologies and devices, with a portfolio focused on cardiovascular and oncologic diseases. Its official materials describe its purpose as restoring healthy blood flow in the vascular system, expanding cancer treatment options, and improving patients’ quality of life. The company also characterizes its solutions as minimally invasive and says its products give physicians tools for diagnosis and treatment. The available evidence does not establish the company’s founding date, founders, early development, acquisitions, product-launch chronology, headquarters, or ownership history. It therefore does not support a reliable dated corporate history or a sequence of historical turning points. The company’s current public-facing materials describe a portfolio intended for healthcare professionals around the world and emphasize high-quality care and patient outcomes. The leadership page provides a snapshot of the company’s named executives and functions. It identifies Jim Clemmer as President, Chief Executive Officer, and Director, alongside leaders for finance, IT, communications, corporate development and strategy, scientific and clinical affairs, legal affairs, cardiovascular and international operations, global supply chain and regulatory affairs, human resources, and oncology and interventional devices. The supplied materials do not give appointment dates for these roles.
Products and positioning
A provider of minimally invasive medical technologies and devices serving cardiovascular and oncologic diagnosis and treatment, with a stated focus on patient outcomes and quality of life.
Cardiovascular medical technologies and devices
The company describes its portfolio as including products that support the diagnosis and treatment of cardiovascular disease.
Oncology medical technologies and devices
The company describes products intended to support oncologic care and expand cancer treatment options.
Recent events
- Unconfirmed
Reported
AngioDynamics signs deal to acquire Eximo Medical[6]
AngioDynamics signed a $66 million deal to acquire Eximo Medical. The deal includes $46 million upfront and up to an additional $20 million in technical and sales-based milestones.
AngioDynamics acquires Eximo Medical[7]
AngioDynamics acquired Eximo Medical and its proprietary 355nm wavelength laser-technology platform. The deal included $46 million in up-front consideration and up to a further $20 million of contingent consideration.
Sources7 sources
- 1Global Leader in Vascular & Oncology Medical Technologies and Devices | AngioDynamicsangiodynamics.com
- 2About Us - Leading Provider of Minimally-Invasive Medical Technologies and Devices | AngioDynamicsangiodynamics.com
- 3AngioDynamics Medical Technologies and Devices | Product Portfolioangiodynamics.com
- 4Leaders Who Make a Difference | AngioDynamicsangiodynamics.com
- 5AngioDynamics (United States)wikidata.org
- 6AngioDynamics签署收购Eximo Medical的协议fiercebiotech.com
- 7AngioDynamics 收购 Eximo Medicaloptics.org
Cite this profile: Cite the canonical profile. /brand-wiki/angiodynamics · Editorial policy · How profiles are compiled